Sign in to view content

Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian nAMD and DME Patients in a Real-World Setting: The PRECISE Study

Ananda Kalevar, MD, FRCS(C), DABO

Video
Published 2020

Related

PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025
Durability of Combination Therapy of Sozinibercept, an Anti-VEGF-C/D 'Trap' With Ranibizumab in nAMD or Aflibercept in DME
Nathan C. Steinle, MD
Annual Meeting Talks
2024
LADDER Trial of the Port Delivery System with Ranibizumab: Initial Study Results
Carl C. Awh, MD, FASRS
Annual Meeting Talks
2018

Category: AMD-Neovascular

See more